Compare · MDXG vs NVO
MDXG vs NVO
Side-by-side comparison of MiMedx Group Inc (MDXG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDXG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 347.9x MDXG ($640.5M).
- Over the past year, MDXG is down 32.8% and NVO is down 21.8% - NVO leads by 11.0 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for MDXG).
- NVO has more recent analyst coverage (25 ratings vs 7 for MDXG).
- Company
- MiMedx Group Inc
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $640.5M
- $222.81B
- 1M return
- +16.80%
- +15.47%
- 1Y return
- -32.76%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 5
- Recent ratings
- 7
- 25
MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MDXG
- Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 3% to 399,566 units (SEC Form 4)
- Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 19,820 shares, decreasing direct ownership by 6% to 309,630 units (SEC Form 4) (withholding tax)
- MiMedx Group Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
- Director Bierman James L was granted 50,913 shares, increasing direct ownership by 24% to 263,684 units (SEC Form 4)
- Director Puhy Dorothy E was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)
- Director Newton Todd was granted 50,913 shares, increasing direct ownership by 12% to 463,684 units (SEC Form 4)
- Director Hawkins William A was granted 50,913 shares, increasing direct ownership by 25% to 254,931 units (SEC Form 4)
- Director Olson Tiffany was granted 50,913 shares, increasing direct ownership by 88% to 108,510 units (SEC Form 4)
- A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S